Article
Treating patients with EGFR-sensitizing mutations: first line or second line--is there a difference?
Journal of clinical oncology : official journal of the American Society of Clinical Oncology - 10 Mar 2013
Mok Tony, Yang Jin-Ji, Lam Kwok-Chi
Abstract excerpt
First-line epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI) is a standard treatment for patients with activating EGFR mutations. Six randomized studies have demonstrated consistent improvement in tumor response rate and progression-free survival over platinum-based combination chemotherapy. The only reason to consider EGFR TKI as second-line therapy is that none of the six comparative studies...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
